From: A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies
Condition | CAR | Target locus (knocked out) | Study model | Ref |
---|---|---|---|---|
ALL | CD19 | Pax5 Ebf1 | C57Bl/6 mice | [106] |
ALL | CD19 | LDLR | NSG mice | [107] |
Ewing sarcoma | Ganglioside G(D2) | EZH2 | VH-64, RM-82, and WE-68 cell lines NSG mice | [108] |
Glioma | EGFRvIII | DGK | U87 MG line NSG mice | [9] |
Liver cancer Ovarian cancer | Mesothelin | TGF-βRII | HepG2 , and OVCAR3 cell line NPG mice | [29] |
ALL Prostate cancer | PSCA CD19 | TRAC B2M PD1 | NSG mice | [109] |
Glioma | CD133 | PD1 | U251 cell line NPG mice | [110] |
Glioma | EGFRvIII | TRAC B2M PD1 | U87 and U251 cell line NSG mice | [111] |
Glioma | EGFRvIII | PD1 | U251 cell line | [24] |
BCL | CD19 | LAG-3 | NSG mice | [112] |
BCL | CD22 | TRAC PD-1 | NALM6 cell line | [113] |
BCL | BCMA CD19 | TRAC | Cell line | [7] |
ALL | CD7 | TRAC | MOLT-3, MOLT-4, HSB-2, and CCRF-CEM cell line NSG mice | [114] |
ALL | CD19 | GM-CSF | Cell line NSG mice | [115] |
ALL | CD19 | GM-CSF | NALM6 and MOLM13 cell line NSG mice | [116] |
BCL | CD19 | TRAC | NSG mice | [117] |
ALL | CD19 | TRAC | NSG mice | [118] |